Table 1 Patient characteristics
Time point | Dx | Last measurement prior to start of IV iloprost |
|---|---|---|
Subjects (n) | 50 | 50 |
Age (years) | 42 (29-58) | 44 (31-63) |
Interval diagnosis and initiation of iloprost (month) | 34 (20-47) | |
Female/male | 34/16 | 34/16 |
NYHA class II/III/IV | 7/30/13 | 1/24/24 |
6MWD (m) | 332 (229-434) | 289 (132-370) # |
PAH-specific therapy | Initial therapy | |
Sildenafil alone | 11 (22%) | 0 (0%) |
ERA alone | 22 (44%) | 2 (4%) |
Inhaled Iloprost alone | 8 (16%) | 0 (0%) |
Sildenafil + ERA | 6 (12%) | 14 (28%) |
Sildenafil + inhaled Iloprost | 3 (6%) | 3 (6%) |
ERA + inhaled Iloprost | 0 (0%) | 5 (10%) |
Triple therapy | 0 (0%) | 26 (52%) |
Hemodynamics | n = 50 | n = 26 |
PRA (mmHg) | 7 (3-13) | 12 (7-16) # |
Ppa (mmHg) | 59 (48-68) | 56 (49-65) |
Ppcw (mmHg) | 7 (5-9) | 9 (7-11) |
CI (L/min/m2) | 2.0 (1.5-2.3) | 1.7 (1.4-1.9) |
PVR (dyn*s*cm-5) | 1, 251 (852-1, 705) | 1, 205 (954-1, 499) |
SVO2 (%) | 58 (54-66) | 58 (54-69) |